Clinical Trial: Efficacy and Safety of Immunoglobulin Plus Firsekibart in Patients With Kawasaki Disease

U.S., July 8 -- ClinicalTrials.gov registry received information related to the study (NCT07686770) titled 'Efficacy and Safety of Immunoglobulin Plus Firsekibart in Patients With Kawasaki Disease' on June 26.

Brief Summary: This study evaluates the efficacy and safety of the addition of Firsekibart to conventional initial treatment (intravenous immunoglobulin [IVIG] plus aspirin) in children with Acute Kawasaki Disease (KD) .

Study Start Date: Aug. 01

Study Type: INTERVENTIONAL

Condition: Kawasaki Disease

Intervention: DRUG: IVIG

IVIG 2g/kg once, given within 8 to 12 hours, with the maximum dose of 60g.

DRUG: Aspirin

Aspirin 30 mg/kg in oral per day (given in 3 divided doses), then 3 to 5 mg/kg per day when fever subsides for 3 d...